Autopsy report · NCT03447262

A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“At Sponsor's Discretion”

The sponsor’s own words in the registry.

Life of this trial

Registered 5 months before it started.
Ran for about 2 years 2 months before it stopped.
484 participants enrolled.
Results were posted on the registry 1 year 5 months after it ended.

Vital statistics

Status: Terminated
Phase: Phase 3
Sponsor: Vertex Pharmaceuticals Incorporated
Sponsor type: Industry
Conditions: Cystic Fibrosis
Interventions: VX-659/TEZ/IVA; IVA
Participants: 484
Sites: 100
Countries: Australia, Canada, Denmark, Germany, Ireland, Israel, Poland, Spain, Switzerland, United Kingdom, United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.